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Parathyroid hormone-related protein (PTHrP) is a key factor in the development of bone metastases, which are a major barrier in
treating prostate cancer patients. In this study, we attempted to identify PTHrP-derived peptides immunogenic in human
histocompatibility leukocyte antigen (HLA)-A24
þ prostate cancer patients. Among four different PTHrP peptides carrying the HLA-
A24 binding motif, both the PTHrP36–44 and PTHrP102–111 peptides efficiently induced peptide-specific cytotoxic T lymphocytes
from peripheral blood mononuclear cells (PBMCs) of HLA-A24
þ prostate cancer patients. Peptide-stimulated PBMCs showed
cytotoxicity against prostate cancer cells in an HLA-A24-restricted manner. Experiments using antibodies and cold inhibition targets
confirmed that their cytotoxicity was dependent on PTHrP peptide-specific and CD8
þ T cells. Immunoglobulin G reactive to the
PTHrP102–111 or PTHrP110–119 peptide was frequently detected in the plasma of prostate cancer patients, suggesting that the
PTHrP102–111 peptide is able to elicit cellular and humoral immune responses in cancer patients. These results indicate that the
PTHrP could be a promising target molecule for specific immunotherapy of HLA-A24
þ prostate cancer patients with metastases.
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Prostate cancer is one of the most common cancers among elderly
men (Greenlee et al, 2000). Prostate cancer frequently metastasises
to bone. Androgen withdrawal therapy has been applied for
patients with bone metastases. Although hormone therapy can
temporarily inhibit the progress of the disease in these patients, a
progression to hormone-refractory prostate cancer inevitably
occurs in most cases. Therefore, the development of new
therapeutic modalities is needed.
Recent advances in tumour immunology have allowed us to
identify the genes encoding human cancer-related antigens, and
the epitopes, which are recognized by cytotoxic T lymphocytes
(CTLs), in patients with various types of cancers (Boon et al, 1997;
Rosenberg, 1999; Renkvist et al, 2001). The identified tumour
antigens and their peptides have been applied for specific
immunotherapy (Nestle et al, 1998; Rosenberg et al, 1998;
Marchand et al, 1999). In the case of prostate cancer, tissue-
specific antigens, which are expressed in the normal prostate, can
also be target molecules for specific immunotherapy for patients
with this disease. Immunotherapy targeting prostate-specific
antigens or prostate-specific membrane antigens has been carried
out, and antitumour effects have been observed in limited cases
(Murphy et al, 1996, 1999; Tjoa et al, 1998; Small et al, 2000; Gulley
et al, 2002).
Parathyroid hormone-related protein (PTHrP) is an autocrine or
paracrine factor that binds to receptors on osteoblasts, and
stimulates bone formation and reabsorption. Parathyroid hor-
mone-related protein has limited homology with PTH at its NH2
terminus, and can bind to the same receptor as PTH, resulting in
similar biological activity (Suva et al, 1987; Juppner et al, 1991).
Parathyroid hormone-related protein plays a variety of physiolo-
gical roles, including calcium transport, keratinocyte differentia-
tion, smooth muscle relaxation, and cartilage development
(Philbrick et al, 1996). In parathyroid cells, a high extracellular
calcium concentration inhibits parathyroid hormone (PTH)
secretion and the proliferation of parathyroid cells as a result of
negative feedback regulation, whereas it evokes further PTHrP
secretion and promotes worsening bone resorption (Sanders et al,
2001). Therefore, PTHrP has been considered to be responsible for
the hypercalcemia associated with malignancy (Guise, 1997). In
addition, prostate cancers have been reported to produce PTHrP
(Francini et al, 2002). These lines of evidence suggest that PTHrP
could be a promising target molecule for the immunotherapy of
prostate cancer patients with bone metastases. In this study, we
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immunogenic in HLA-A24
þ prostate cancer patients.
MATERIALS AND METHODS
Patients
Informed consent was obtained from all of the HLA-A24
þ prostate
cancer patients and HLA-A24
þ healthy volunteers who were
enrolled in this study. None of the participants were infected with
HIV. In total, 20ml of peripheral blood was obtained, and the
PBMCs were prepared by Ficoll-Conray density gradient centrifu-
gation. The expression of HLA-A24 molecules on the PBMCs of the
cancer patients and healthy donors was determined by flow
cytometry.
Cell lines
C1R-A24 is an HLA-A*2402-expressing subline of C1R lymphoma
(Dr M Takiguchi, Kumamoto University, Japan). LNCaP is an
HLA-A24 negative prostate cancer cell line. To establish LNCaP
cells that stably express HLA-A24 molecules (designated as
LNCaP-A24), an HLA-A*2402 gene was inserted into a
pcDNA3.1/Hygro vector (Invitrogen, CA, USA), and electroporated
into the LNCaP cell line (ATCC, Manassas, VA, USA), and
selection was carried out with hygromycin B (Invitrogen) at a dose
of 170mgml
 1. All cell lines were maintained in RPMI-1640
medium (Gibco BRL, Grand Island, NY, USA) supplemented with
10% FCS.
Peptides
Four PTHrP-derived peptides (listed in Table 1) were prepared
based on the HLA-A24 binding motif (Parker et al, 1994;
Rammensee et al, 1995). All peptides were of 490% purity and
were purchased from Biologica Co., Nagoya, Japan. Influenza (Flu)
virus-derived (RFYIQMCYEL), EBV-derived (TYGPVFMCL), and
HIV-derived peptides (RYLRQQLLGI) with the HLA-A24 binding
motif were used as controls. All peptides were dissolved with
DMSO at a dose of 10mgml
 1.
Assay for peptide-specific CTLs in PBMCs
The assay for the detection of peptide-specific CTLs in PBMCs was
performed according to a previously reported method (Hida et al,
2002). In brief, PBMCs (1 10
5 cells per well) were incubated with
10mgml
 1 of each peptide in a U-bottom-type 96-well micro-
culture plate (Nunc, Roskilde, Denmark) at a volume of 200mlo f
culture medium. The culture medium consisted of 45% RPMI-
1640, 45% AIM-V medium (Gibco BRL), 10% FCS, 100Uml
 1 of
IL-2, and 0.1mM MEM nonessential amino-acid solution (Gibco,
BRL). Half of the culture medium was removed and replaced with
new medium containing a corresponding peptide (20mgml
 1)
every 3 days. On the 15th day of culture, the cultured cells were
separated into four wells; two wells were used for the PTHrP
peptide-pulsed C1R-A24 cells, and the other two wells were used
for the HIV peptide-pulsed C1R-A24 cells. After an 18-h
incubation period, the supernatants were collected, and the level
of IFN-g was determined by ELISA (limit of sensitivity:
10pgml
 1).
Table 1 Reactivity of PTHrP peptide-stimulated PBMCs from HLA-A24
+ healthy donors and prostate cancer patients
Peptides
Name PTHrP36–44 PTHrP102–111 PTHrP25–34 PTHrP110–119 Flu EBV
PBMCs Amino-acid sequence RAVSEHQLL RYLTQETNKV RSVEGLSRRL KVETYKEQPL RFYIQMCTEL TYGPVFMCL
Derived from Score
a 14.4 19.8 17.3 14.4
IFN-g production (pg/ml)
b
Healthy donors
#1 154 352 10 394 306 0
#2 156 132 8 17 0 207
#3 497 0 7 20 17 0
#4 0 0 37 2 59 14
#5 184 0 166 38 0 27
#6 1354 0 0 357 124 168
#7 166 38 0 0 1017 0
#8 0 194 0 1017 0 0
#9 0 5624 5 61 123 228
#10 0 168 1354 0 0 3
Total 6/10 5/10 2/10 3/10 4/10 3/10
Cancer patients
#1 180 154 145 0 0 15
#2 122 138 15 9 5 0
#3 699 8 17 38 0 21
#4 31 105 24 19 0 159
#5 799 28 16 10 130 20
#6 500 4 1 14 198 15
#7 317 0 0 0 ND ND
#8 4 1060 411 23 115 189
#9 17 101 1 0 709 3
#10 180 198 196 118 40 27
Total 7/10 6/10 3/10 1/10 4/9 2/9
aThe score represents the estimated half-time of dissociation of the PTHrP peptides binding to HLA-A24 molecules.
bThe PBMCs of HLA-A24
+ healthy donors and prostate
cancer patients were stimulated in vitro with the indicated PTHrP peptide, as described in Material and Methods. On the 15th day, the cultured PBMCs were tested for their
reactivity to C1R-A24 cells, which were prepulsed with the corresponding peptide or the HIV peptide. The values represent the mean of two wells, and the background IFN-g
production in response to the HIV peptide was subtracted. Significant values (Po0.05 by two-tailed Student’s t-test) are underlined. ND¼not done.
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After in vitro stimulation with the PTHrP peptides, the peptide-
stimulated PBMCs were additionally cultured with 100Uml
 1 IL-2
for approximately 10 days, in order to obtain a sufficient number
of cells to carry out a cytotoxicity assay. These cells were
then tested for cytotoxicity against both LNCaP and LNCaP-A24
by a 6-h
51Cr-release assay. A total of 2000
51Cr-labelled cells
per well were cultured with effector cells in 96-round-well plates at
the indicated effector/target ratios. In some experiments, either
anti-HLA class I (W6/32: mouse IgG2a), anti-HLA-DR (L243:
mouse IgG2a), anti-CD4 (NU-TH/I: mouse IgG1), anti-CD8 (NU-
TS/C: mouse IgG2a), or anti-CD14 (H14: mouse IgG2a) mAb was
added to the wells at a dose of 20mgml
 1 at the initiation of the
assay.
Cold inhibition assay
The specificity of the PTHrP peptide-stimulated CTLs was
confirmed by a cold inhibition assay. In brief,
51Cr-labelled
target cells (2 10
3 cells per well) were cultured with the CTLs
(4 10
4 cells per well) in 96-round-well plates with 2 10
4 cold
target cells. C1R-A24 cells, which were prepulsed with either the
HIV peptide or a corresponding PTHrP peptide, were used as cold
targets.
Detection of peptide-specific IgG
The peptide-specific IgG levels in the plasma were measured by
ELISA, as previously reported (Nakatsura et al, 2002; Ohkouchi
et al, 2002). In brief, peptide (20mg per well)-immobilised plates
were blocked with Block Ace (Yukijirushi, Tokyo, Japan) and
washed with 0.05% Tween-20-PBS, after which 100ml per well of
plasma sample diluted with 0.05% Tween-20-Block Ace was added
to the plate. After a 2-h incubation at 371C, the plates were washed
and further incubated for 2-h with a 1:1000-diluted rabbit anti-
human IgG (g-chain-specific) (DAKO, Glostrup, Denmark). The
plates were washed, and then 100ml of 1:100-diluted goat anti-
rabbit IgG-conjugated horseradish peroxidase (EnVision, DAKO)
was added to each well, and the plates were then incubated at room
temperature for 40min. After the plates were washed once, 100ml
per well of tetramethyl benzidine substrate solution (KPL,
Guildford, UK) was added, and the reaction was stopped by the
addition of 1 M phosphoric acid. The values are shown as optical
density (OD) unitsml
 1. IgG reactive to a corresponding PTHrP
peptide was judged to be positive when the difference of the OD in
1:100-diluted plasma exceeded 0.05. To confirm the specificity of
IgG to the indicated PTHrP peptide, sample plasma was cultured
with plates coated with either the corresponding PTHrP peptide or
an irrelevant PTHrP peptide. Thereafter, the levels of PTHrP
peptide-specific IgG in the resulting supernatant were determined
by ELISA.
Statistics
The statistical significance of the data was determined using a two-
tailed Student’s t-test. A P-value of less than 0.05 was considered to
be statistically significant.
RESULTS
Induction of PTHrP peptide-specific CTLs from HLA-
A24
þ healthy donors and prostate cancer patients
First, four PTHrP-derived peptides were prepared based on their
binding affinity to HLA-A24 molecules (Parker et al, 1994;
Rammensee et al, 1995) (Table 1). Although the PTHrP1–36
peptide is a propeptide (Suva et al, 1987; Juppner et al, 1991), the
PTHrP25–34 peptide was included. With regard to the difference in
amino acids, three amino acids were found to differ between the
PTHrP36–44 peptide and PTH, and all of the amino acids were
found to differ between the other three PTHrP peptides and PTH.
Next, to investigate the immunogenicity of these four PTHrP
peptides, the PBMCs of 10 HLA-A24
þ healthy donors and 10
HLA-A24
þ prostate cancer patients were stimulated with each of
four PTHrP peptides, and were then examined for their IFN-g
production in response to C1R-A24 cells, which were prepulsed
with either a corresponding PTHrP peptide or the HIV peptide
(Table 1). Flu- and BEV-derived peptides were used as controls.
The assay was carried out in quadruplicate. The cultured cells in
one well were separated into four wells. Two wells were used for
the PTHrP peptide-pulsed C1R-A24 cells, and the other two wells
for the HIV peptide-pulsed C1R-A24 cells. The background IFN-g
production in response to the HIV peptide was subtracted, and the
results that showed the best response are shown in Table 1. The
successful induction of peptide-specific CTLs was judged to be
positive when significant values (Po0.05 by two tailed Student’s t-
test) were observed. The results showed that the PTHrP36–44,
PTHrP102–111, PTHrP25–34, and PTHrP110–119 peptides induced
peptide-specific CTLs in six, five, two, and three of 10 HLA-A24
þ
healthy donors, respectively. These PTHrP peptides also induced
peptide-specific CTLs in seven, six, three, and one of 10 HLA-
A24
þ prostate cancer patients, respectively. The net IFN-g
production of the cases with 10 HLA-A24
þ prostate cancer
patients in response to the corresponding PTHrP peptide or the
HIV peptide are shown in Figure 1. In total, these findings indicate
that both the PTHrP36–44 and PTHrP102–111 peptides are promis-
ing candidates to generate peptide-specific CTLs from HLA-A24
þ
prostate cancer patients.
Induction of prostate cancer-reactive CTLs using
PTHrP36–44 and PTHrP102–111 peptides
In order to investigate the HLA-A24-restricted and prostate
cancer-reactive cytotoxicity of peptide-stimulated PBMCs, we
prepared an HLA-A24-expressing LNCaP cell line, which we
designated LNCaP-A24 (Figure 2). LNCaP has previously been
reported to produce PTHrP (Francini et al, 2002). A parental
LNCaP cell line was negative for the cell surface expression of
HLA-A24 molecules, whereas the LNCaP-A24 cell line expressed
HLA-A24 molecules on their cell surface. It was then determined
whether PBMCs stimulated by either the PTHrP36–44 or PTHrP102–
111 peptide could induce prostate cancer-reactive CTLs from HLA-
A24
þ healthy donors and prostate cancer patients. PBMCs from
HLA-A24
þ healthy donors and cancer patients were repeatedly
stimulated with the indicated PTHrP peptide, based on the culture
protocol described in Materials and Methods. After confirming
that these peptide-stimulated cells could produce IFN-g in
response to PTHrP peptide-pulsed C1R-A24 cells, the peptide-
stimulated PBMCs were examined for their cytotoxicity against
three targets. It was found that the PTHrP peptide-stimulated
PBMCs from HD#2, Pt#1, and Pt#2 produced higher levels of IFN-g
in response to the corresponding PTHrP peptide-pulsed C1R-A24
cells than to the HIV peptide-pulsed C1R-A24 cells (Figure 3A).
These peptide-stimulated PBMCs also showed higher levels of
cytotoxicity against the LNCaP-A24 cell line than against the
LNCaP line and HLA-A24
þ PHA-induced T cell blasts (Figure 3B).
In addition, their cytotoxicity against LNCaP-A24 was significantly
inhibited by the addition of anti-HLA-class I and anti-CD8 mAbs,
but not by the addition of other anti-HLA-class II, anti-CD4, or
anti-CD14 mAbs (Figure 4A). Furthermore, their cytotoxicity
against the LNCaP-A24 cell line was significantly suppressed by the
addition of the corresponding PTHrP peptide-pulsed C1R-A24
cells, as a cold target, but this suppression was not observed with
the addition of HIV peptide-pulsed C1R-A24 cells (Figure 4B). In
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Figure 1 Induction of PTHrP peptide-specific CTLs from the PBMCs of HLA-A24
þ prostate cancer patients. PBMCs from 10 HLA-A24
þ prostate
cancer patients were stimulated in vitro with the PTHrP peptides indicated, as described in Materials and Methods. On the 15th day, the peptide-stimulated
cells were cultured with C1R-A24 cells, which were prepulsed with an HIV peptide (open bar) and the indicated PTHrP peptide (closed bar) for 18-h. The
levels of IFN-g in the supernatants were then determined by ELISA. *Po0.05 was considered statistically significant.
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from cancer patients showed cytotoxicity against another prostate
cancer cells PC-93-A24, stably expressed the HLA-A24 molecules
and produced PTHrP (data not shown). These results indicate that
both the PTHrP36–44 and PTHrP102–111 peptides have the potential
to induce prostate cancer-reactive CTLs from HLA-A24
þ prostate
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Figure 2 An HLA-A24-expressing LNCaP cell line. Flow cytometric analysis was performed on the LNCaP and LNCaP-A24 cells. These cells were
stained with anti-HLA-A24 mAb, followed by FITC-conjugated anti-mouse IgG mAb. The dotted lines represent staining without the first mAb.
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Figure 3 Induction of HLA-A24-restricted and prostate cancer-reactive CTLs from the PBMCs of healthy donors and cancer patients. (A) PBMCs from
one HLA-A24
þ healthy donor (HD #2) and from two HLA-A24
þ prostate cancer patients (Pt #1 and Pt #2) were stimulated in vitro with the indicated
PTHrP peptides, as described in Materials and Methods. On the 15th day, half of the cultured cells were harvested, pooled from four wells, and cultured with
C1R-A24 cells, which were prepulsed with an HIV peptide (open symbol) and the indicated PTHrP peptide (closed symbol) for 18-h. The levels of IFN-g in
the supernatants were then determined by ELISA. (B) Thereafter, these cells were examined for their cytotoxicity against the LNCaP cells (HLA-A24
-),
LNCaP-A24 cells (HLA-A24
þ), and PHA-blastoid T cells (HLA-A24
þ). A 6-h
51Cr-release assay was performed. Values represent the mean of triplicate
assays. *Po0.05 was considered statistically significant.
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was dependent on PTHrP peptide-specific CD8
þ T cells.
Detection of IgG reactive to the PTHrP peptides
We previously reported that IgGs reactive to CTL epitope peptides
were detected in healthy donors and cancer patients (Nakatsura
et al, 2002; Ohkouchi et al, 2002). IgGs reactive to prostate-related
antigens were also detected in healthy donors and prostate cancer
patients (Harada et al, 2003a; Kobayashi et al, 2003; Matsueda et al,
2004) Therefore, we attempted to determine whether IgG reactive
to four PTHrP-derived peptides could be detected in the plasma of
cancer patients and healthy donors. The result was that IgG
reactive to either the PTHrP102–111 or the PTHrP109–119 peptide
Antibody
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Figure 4 CD8
þ T-cell-dependent and PTHrP peptide-specific cytotoxicity against LNCaP-A24 cells. (A) The PTHrP peptide-stimulated PBMCs,
described in Figure 2, were examined for their cytotoxicity against the LNCaP-A24 cell line, with or without anti-HLA class I, anti-HLA class II, anti-CD4, anti-
CD8, or anti-CD14 mAb at a dose of 20mgml
 1. The values represent the mean of triplicate assays. *Po0.05 was considered statistically significant. (B) The
cytotoxicity against the LNCaP-A24 cell line (2 10
3 cells per well) was also examined in the presence of unlabelled C1R-A24 cells (2 10
4 cells per well),
which were prepulsed with the HIV peptide or a corresponding PTHrP peptide. The values represent the mean of triplicate assays. *Po0.05 was considered
statistically significant.
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prostate cancers (Table 2). Representative results are in Figure 5A.
However, IgG reactive to the PTHrP36–44 peptide was detected in
three of 10 healthy donors and one of 10 prostate cancer patients,
respectively. No IgG reactive to PTHrP25–34 was detected in any of
the healthy donors or cancer patients. The levels of PTHrP
peptide-specific IgG were significantly diminished by culturing the
plasma in the corresponding PTHrP peptide-coated wells
(Figure 5B). This peptide-specific absorption demonstrated the
validity of the present assay system.
DISCUSSION
Prostate cancer appears to be a good target for the development of
specific immunotherapies (Harada et al, 2003b). In recent years,
our group has attempted to identify epitope peptides derived from
prostate-related antigens that would be able to generate prostate
cancer-reactive CTLs from prostate cancer patients (Inoue et al,
2001; Kobayashi et al, 2003; Harada et al, 2003a; Matsueda
et al, 2004). However, one major obstacle encountered when
treating prostate cancer patients is the treatment of bone
metastases, as prostate cancer frequently metastasises to the bone
tissue. Therefore, we undertook the present study to identify
epitope peptides that could potentially be suitable for specific the
immunotherapy of HLA-A24
þ prostate cancer patients with
metastases.
PTHrP is known to be a key agent in the development of bone
metastasis in cases of prostate cancer, and prostate cancer cells has
been reported to produce PTHrP (Francini et al, 2002). These lines
of evidence indicate that PTHrP could be a good target for the
development of specific immunotherapies against metastatic
prostate cancer. Indeed, PTHrP59–68 and PTHrP165–173 peptides
have been reported to be candidates for such specific immu-
notherapy of HLA-A2
þ prostate cancer patients (Guise, 1997;
Francini et al, 2002). In this study, we identified new PTHrP
peptides that have the potential to generate prostate cancer-
specific CTLs in HLA-A24
þ prostate cancer patients, in order to
extend the possibility of PTHrP peptide-based anticancer vaccine.
We revealed that both the PTHrP36–44 and the PTHrP102–111
peptides have the potential to induce prostate cancer-reactive
CTLs in HLA-A24
þ prostate cancer patients. PBMCs from HLA-
A24
þ prostate cancer patients showed peptide-specific IFN-g
production in six or seven of 10 patients when stimulated with the
PTHrP102–110 and PTHrP36–44 peptide, respectively. More im-
portantly, PBMCs that were stimulated with these PTHrP peptides
showed cytotoxicity against prostate cancer cells in an HLA-A24-
restricted manner. These results indicate that these two PTHrP
peptides are immunogenic, and therefore potentially useful for the
specific immunotherapy of HLA-A24
þ prostate cancer patients
with metastases.
The PTHrP36–44 and the PTHrP102–110 peptides also induced
peptide-specific and tumour-reactive CTLs from the PBMCs of
HLA-A24
þ healthy donors. This result is consistent with that of a
previous report demonstrating the induction of PTHrP peptide-
specific CTLs from the PBMCs of HLA-A2
þ healthy donors
(Francini et al, 2002). As the PTHrP36–44 peptide shares three
amino acids with PTH, and because there is no homology between
the PTHrP102–111 peptide and PTH, crossreactivity between the
PTHrP peptides and PTH could be excluded. Low levels of PTHrP
have been sporadically detected in keratinocytes, uterus, and
mammary glands during lactation (Tian et al, 1993). Recent
advances in tumour immunology have revealed that self-antigens
on human cancer cells are the most prevalent antigens recognized
by the immune system (Rosenberg, 1999; Renkvist et al, 2001).
CTL precursors reactive to nonmutated self-antigens may circulate
in the peripheral blood of both certain healthy donors and cancer
patients.
Here, we investigated whether or not IgG against PTHrP
peptides would be detectable in plasma from HLA-A24
þ healthy
donors and prostate cancer patients, because the antibodies
against CTL epitope peptides had already been observed in certain
cancer patients and healthy donors (Nakatsura et al, 2002;
Ohkouchi et al, 2002). We also previously reported that IgG
reactive to peptides derived from prostate-related antigens was
frequently detectable in healthy donors and prostate cancer
patients (Harada et al, 2003a; Kobayashi et al, 2003; Matsueda
et al, 2004). In this study, IgG reactive to either the PTHrP102–111
peptide or PTHrP110–119 peptide was frequently detected in
healthy donors as well as in prostate cancer patients. This means
that the PTHrP102–111 peptide was recognized by both the cellular
and humoral immune systems. Although we do not yet have a clear
understanding of the roles played by peptide-specific IgG in
antitumour immune responses, our clinical trials revealed that a
peptide vaccination frequently resulted in the induction of IgG
reactive to the CTL epitope peptides which were administered
(Noguchi et al, 2003; Tanaka et al, 2003). In addition, the induction
of IgG reactive to the vaccinated peptides was positively correlated
with longer survival of advanced lung cancer patients (Mine et al,
2003). As regards the use of a peptide vaccination in cases of
gastric cancer, prolonged survival has been observed in patients
showing not only cellular, but also humoral immune responses to
vaccinated peptides (Sato et al, 2003). In addition, the induction of
IgG reactive to the administered peptides was correlated with a
clinical response among patients with recurrent gynecologic
cancer (Tsuda et al, 2004). Furthermore, we recently analysed
113 vaccinated patients with various types of cancers, and revealed
that the augmentation of peptide-specific IgG after peptide
vaccination could be a laboratory marker for the prediction of
prolonged survival in vaccinated cancer patients compared to
the induction of peptide-specific CTLs or the delayed-type
hypersensitivity test (Mine et al, 2004). Moreover, we recently
observed that peptide vaccination with a 9-mer CTL epitope
peptide could induce peptide-specific and HLA-DR-restricted
CD4
þ T cells in vivo (Harada et al, 2004). As these findings
provide circumstantial evidence, further clinical study is needed to
Table 2 IgG reactive to the PTHrP peptides in plasma of HLA-A24
+ healthy donors and prostate cancer patients
Healthy donors Prostate cancer patients
Peptides #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Total #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 Total
PTHrP36–44       +++   3/10     +        1/10
PTHrP102–111 +   +++  + + + + 8/10 + +   +++++   7/10
PTHrP25–34             0/10             0/10
PTHrP110–119 +++  +   + + + + 8/10 + +    ++++ + 7/10
IgG reactive to the corresponding peptide was judged to be positive when the difference in the OD in 1:100-diluted plasma exceeded 0.05. The cutoff level (OD: 0.05) was
determined based on the levels of anti-HIV peptide IgG in HIV-negative healthy donors.
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Figure 5 IgG reactive to the PTHrP peptides in plasma from healthy donors and prostate cancer patients. (A) Representative results from six healthy
donors and six prostate cancer patients are shown. These values are shown as optical density (OD), and the responses to the HIV peptide were subtracted.
IgG reactive to a corresponding PTHrP peptide was judged to be positive when the difference of the OD in 1:100-diluted plasma exceeded 0.05. The cutoff
level (OD: 0.05) was determined based on the levels of anti-HIV peptide IgG in HIV-negative healthy donors. (B) To confirm the specificity of IgG to the
indicated PTHrP peptides, 100ml of sample plasma from either HD #1 and Pt #6 was cultured in a plate precoated with either a corresponding PTHrP
peptide or an irrelevant PTHrP peptide. Thereafter, the levels of IgG reactive to the PTHrP102–111 peptide or the PTHrP110–119 peptide in the resultant
samples were determined by ELISA.
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cancer immunotherapy.
In conclusion, we identified new two PTHrP-derived peptides
that are immunogenic in HLA-A24
þ prostate cancer patients. The
frequencies of the HLA-A24 allele are relatively high throughout the
world (Imanishi et al, 1992). The information provided here might
increase the possibility of treating HLA-A24
þ prostate cancer
patients with metastases using peptide-based immunotherapy.
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